An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the Board of Directors of Trubion Pharmaceuticals:
What is one aspect of your company that you feel would be most attractive or exciting to investors?
We currently have three product candidates in the clinic with two, strategic collaborations underlying their development – Wyeth for our CD20 programs and Facet for our CD37 programs. Data disclosures later this year from key clinical trials for each of these product candidates provide meaningful catalysts for investors in the short term. Trubion has the financial strength to move its clinical programs forward while continuing to expand our proprietary pipeline. Based on our current development plans, we expect that our existing cash and proceeds from our strategic collaborations will be sufficient to fund high priority programs into 2012.
Can you describe the top priorities or upcoming milestones for your company?
We are focused on advancing the clinical and preclinical development of priority programs based on our novel protein therapeutic technology platforms, including three lead candidates in human clinical evaluation:
- TRU-015 (partnered with Wyeth Pharmaceuticals), our lead SMIP candidate for the treatment of rheumatoid arthritis (RA), recently yielded positive data from a Phase 2b re-treatment study earlier this year. We expect to announce data by end of year from an additional P2b study designed to identify an optimal dosing regimen.
- TRU-016 (co-developed with Facet Biotechnology) is for the treatment of b-cell malignancies, including chronic lymphocytic leukemia (CLL), and is currently in Phase 1/2 development. Preliminary Phase 1 data is promising, and we expect to announce additional data from the Phase 2 portion of the study by the end of the year.
- SBI-087 (partnered with Wyeth Pharmaceuticals), is a fully-humanized CD20-directed SMIP being developed in two therapeutic areas – RA and systemic lupus erythematosus. Both programs are in Phase 1 clinical development, we expect to announce data from the Phase 1 RA trial by the end of the year.